Xbrane announces four more patents granted
Xbrane Biopharma AB (publ) (" Xbrane" or the "Company") (Nasdaq Stockholm: XBRANE) has been granted four new patents by the Swedish Patent and Registration Office (PRV). The patents resulted from the development of XdivaneTM (an Opdivo® biosimilar) and form the foundation for a broadening of the platform technology for the production of antibodies with high productivity and thereby low production costs in mammalian cells. This broadening is critical for Xbrane's future portfolio of biosimilars since a majority of biological drugs on the market today are manufactured in mammalian cells.
Xbrane Biopharma AB (publ) (" Xbrane" or the "Company") (Nasdaq Stockholm: XBRANE) has been granted four new patents by the Swedish Patent and Registration Office (PRV). The patents resulted from the development of XdivaneTM (an Opdivo® biosimilar) and form the foundation for a broadening of the platform technology for the production of antibodies with high productivity and thereby low production costs in mammalian cells. This broadening is critical for Xbrane's future portfolio of biosimilars since a majority of biological drugs on the market today are manufactured in mammalian cells.
